Will our cardiomyopathy patients accept gene therapy?

P. A. Doevendans; C. Kupatt; M. Giacca; P. Glijnis

doi:10.1007/s12471-022-01665-z

Will our cardiomyopathy patients accept gene therapy?

P. A. Doevendans^*, C. Kupatt, M. Giacca, P. Glijnis

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

12 Downloads (Pure)

Abstract

Novel techniques such as gene therapy are becoming available in an attempt to cure inherited diseases. Before these new therapies can be offered to patients, we need to be aware of potential reservations or objections, not only from patients and their surroundings but also from the public. In addition, legal issues and costs need attention before curative gene therapy can be applied in the clinic. As this therapeutic approach is closer to becoming a reality, now is the right time to start the debate.

Original language	English
Pages (from-to)	343-344
Number of pages	2
Journal	Netherlands Heart Journal
Volume	30
Issue number	7-8
DOIs	https://doi.org/10.1007/s12471-022-01665-z
Publication status	Published - Jul 2022

Keywords

Cardiomyopathy
Gene editing
Viral vectors

Access to Document

10.1007/s12471-022-01665-zLicence: CC BY

s12471-022-01665-zFinal published version, 164 KBLicence: CC BY

Cite this

@article{94aa330999e244228158006b0fd3c57d,

title = "Will our cardiomyopathy patients accept gene therapy?",

abstract = "Novel techniques such as gene therapy are becoming available in an attempt to cure inherited diseases. Before these new therapies can be offered to patients, we need to be aware of potential reservations or objections, not only from patients and their surroundings but also from the public. In addition, legal issues and costs need attention before curative gene therapy can be applied in the clinic. As this therapeutic approach is closer to becoming a reality, now is the right time to start the debate.",

keywords = "Cardiomyopathy, Gene editing, Viral vectors",

author = "Doevendans, {P. A.} and C. Kupatt and M. Giacca and P. Glijnis",

note = "Funding Information: The first ocular gene therapy that was approved by the American Food and Drug Administration, voretigene neparvovec-rzyl (Luxturna; Spark Therapeutics, USA), uses an AAV2 vector to deliver a functional copy of the RPE65 gene for the treatment of Leber congenital amaurosis type 2. This autosomal recessive inherited eye disease leads to impaired vision or even blindness at birth, but the phenotype is variable. Clinical trials to evaluate safety and effectiveness are ongoing, [] supported by the Foundation Fighting Blindness ( www.fightingblindness.org ). While this therapy does not provide a cure, it leads to prolonged normal protein expression. In Australia, a protocol has been approved to evaluate the ethics of ocular gene therapy []. The research group involved is in the process of developing a new {\textquoteleft}Attitudes to Gene Therapy for the Eye{\textquoteright} tool. Funding Information: P. A. Doevendans has received a grant from the Netherlands Organisation for Health Research and Development (ZonMw) (PSIDER-Heart) and the Leducq Foundation (CUREPLaN). Publisher Copyright: {\textcopyright} 2022, The Author(s).",

year = "2022",

month = jul,

doi = "10.1007/s12471-022-01665-z",

language = "English",

volume = "30",

pages = "343--344",

journal = "Netherlands Heart Journal",

issn = "1568-5888",